| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.11. | T-Therapeutics raises $133M series B for bispecific pipeline with Big Pharma backers in tow | ||
| 04.11. | Charles River teams up with Ipsen to use virtual control groups in toxicology studies | ||
| 04.11. | nPhase rakes in $30M to expand AI-native clinical data platform | ||
| 04.11. | Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs | ||
| 04.11. | Minghui grants ASKA Japanese rights to sub-q TED candidate in $440M deal | ||
| 04.11. | Blackstone Life Sciences teams up with Boston Scientific in $455M heart pump deal | ||
| 04.11. | Smith+Nephew held failed talks with J&J over potential orthopedics combination | ||
| 04.11. | AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera | ||
| 04.11. | Ultragenyx shrinks workforce and axes assets to halve R&D spend | ||
| 04.11. | Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic | ||
| 04.11. | Novo's CEO still looking for deals to 'close some of the gaps,' as misfires hit profits | ||
| 04.11. | AbbVie invests £120M in UK, including new R&D headquarters | ||
| 03.11. | Abbott's Tectonic test looks to shift artery disease treatment with 'early' win | ||
| 03.11. | Rhythm doubles down on LG Chem obesity license, raising payout to as much as $855M | ||
| 03.11. | Philips sets aside $322M for proposed DOJ settlement over sleep apnea device recall | ||
| 03.11. | AbbVie abandons phase 2 solid tumor drug over 'limited benefit' | ||
| 03.11. | Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate | ||
| 03.11. | BioArctic left out in the cold as Novartis walks away from $800M neuro collab | ||
| 02.11. | FDA grants uniQure's Huntington's gene therapy priority review, teeing up 'defining milestone' | ||
| 02.11. | OpenAI-funded Biossil snags Theriva's unwanted antibiotic degrader portfolio for up to $91M | ||
| 02.11. | Teva ends trial of one of its original line-up of innovative meds over futility | ||
| 02.11. | FDA dims Bright Minds' outlook with partial hold on seizure trial over toxicity in mice | ||
| 02.11. | Lower dose of Tiziana's MS drug reduces neuroinflammation, while higher dose struggles | ||
| 02.11. | China's InventisBio delivers competitive TYK2 data in phase 3 psoriasis win | ||
| 30.10. | Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials |